These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 31760310)

  • 1. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
    Hsu KH; Huang YH; Tseng JS; Chen KC; Ku WH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
    Lung Cancer; 2019 Jan; 127():37-43. PubMed ID: 30642549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
    BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
    Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
    Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
    Cai Y; Wu H; Shi X; Dong Y; Chang X; Zhang L; Zhou L; Su D; Yang M
    BMC Cancer; 2020 Feb; 20(1):148. PubMed ID: 32093629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis.
    Lan B; Wang Y; Wu J; Wang K; Wang P
    Medicine (Baltimore); 2021 Aug; 100(34):e27038. PubMed ID: 34449486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
    Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
    Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
    Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
    Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.
    Su S; Dong ZY; Xie Z; Yan LX; Li YF; Su J; Liu SY; Yin K; Chen RL; Huang SM; Chen ZH; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Nov; 13(11):1668-1675. PubMed ID: 30056164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.